Autolus Therapeutics (NASDAQ:AUTL) Issues Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21), FiscalAI reports. The business had revenue of $41.24 million for the quarter, compared to analyst estimates of $39.54 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. During the same quarter last year, the firm earned ($0.30) EPS.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL revenue accelerated: Q3 net product revenue rose 95% year over year to $41.2 million, and Autolus now expects full-year 2026 revenue of at least $150 million, above its prior guidance range.
• Commercial reach expanded ahead of plan, with 90 U.S. centers authorized against an 80-center goal and 18 centers authorized in the U.K.; management said the U.K. launch is going well.
• Gross margin improved to 57% in Q3 and 44% year to date. Management attributed the gains to higher production volumes and manufacturing efficiencies, saying the company expects continued gradual improvement.
• Cash, cash equivalents, and marketable securities totaled $248.4 million at quarter-end; the company expects funding into Q2 2028, assuming anticipated AUCATZYL sales and $25 million from the second tranche of its credit facility. Q3 net loss was $55.1 million.
• Autolus moved its first BOBCAT progressive MS data presentation to October 2027 to allow longer follow-up, citing expert feedback that at least 12 months is needed to assess clinical outcomes. Management said the study remains on track, but the data update will come later than previously anticipated.

Autolus Therapeutics Stock Down 4.9%

Shares of AUTL traded down $0.07 on Wednesday, reaching $1.25. The stock had a trading volume of 2,131,426 shares, compared to its average volume of 1,855,381. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. Autolus Therapeutics has a 12-month low of $1.12 and a 12-month high of $2.58. The firm has a market capitalization of $334.03 million, a price-to-earnings ratio of -1.18 and a beta of 2.32. The company has a 50-day simple moving average of $1.76 and a 200-day simple moving average of $1.66.

Analyst Upgrades and Downgrades

AUTL has been the subject of a number of analyst reports. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. UBS Group reissued a “buy” rating on shares of Autolus Therapeutics in a research note on Wednesday. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.